In the context of vitiligo pathogenesis, systemic and epidermal levels of IL-17 have been found to be significantly elevated in vitiligo patients, with increased IL-17 signaling proposed as a biomarker for disease activity [16, 29–35]. This evidence concerns the gene IL17A and vitiligo.